Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Accumulated Expenses (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Accumulated Expenses for 2 consecutive years, with $496000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 95.11% to $496000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $496000.0 through Dec 2025, down 95.11% year-over-year, with the annual reading at $496000.0 for FY2025, 95.11% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $496000.0 at NRX Pharmaceuticals, down from $9.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $10.1 million in Q4 2024, with the low at $496000.0 in Q4 2025.